logo

Wanbury’s Plant Clears South Korea Inspection With Zero Observations; Shares Fall 0.25%

Authored By HDFC SKY | Published at: Nov 20, 2026 10:57 AM IST

Wanbury Limited has successfully completed a three-day current Good Manufacturing Practice (cGMP) inspection by South Korea’s Ministry of Food and Drug Safety (MFDS) at its Tanuku API manufacturing facility in Andhra Pradesh. The inspection concluded with zero observations. Wanbury shares traded marginally lower during morning trading on November 20, 2026.

Stocks in News
WANBURY
₹181.81
0.08%
Wanbury’s Plant Clears South Korea Inspection With Zero Observations; Shares Fall 0.25%

Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

Mumbai, November 20: Wanbury Limited’s API (active pharmaceutical ingredient) manufacturing facility in Tanuku, Andhra Pradesh, has cleared a three-day inspection by South Korea’s MFDS (Ministry of Food and Drug Safety) with zero observations. The inspection covered the plant’s compliance with pharmaceutical manufacturing standards.

Wanbury’s Tanuku Facility Completes South Korea MFDS Inspection With Zero Observations

According to the company’s November 20 regulatory disclosure, two senior inspectors from South Korea’s MFDS conducted a three-day inspection at Wanbury’s Tanuku API manufacturing facility. The inspection covered the plant’s compliance with current Good Manufacturing Practice standards and concluded without any observations. The outcome indicates that the inspectors did not identify deficiencies requiring formal observations during the assessment. The latest inspection follows a similar regulatory assessment at Wanbury’s Patalganga manufacturing facility in April 2026. That inspection, also conducted by South Korea’s MFDS, concluded with zero observations. The two inspection outcomes highlight the company’s efforts to maintain manufacturing quality and compliance with international pharmaceutical standards. Wanbury said it continues to strengthen its quality systems and manufacturing practices in line with evolving global regulatory requirements. The South Korean inspection outcome is separate from the USFDA’s November 16 classification of the Tanuku facility as Official Action Indicated (OAI). Wanbury previously stated that the USFDA classification was not expected to disrupt existing product supplies or business continuity. The MFDS inspection result is therefore a positive development under South Korean regulatory standards, but does not change the facility’s separate USFDA inspection classification.

Stock Market Snapshot

Wanbury share price were trading at approximately ₹181.20 on Friday, November 20, 2026, down ₹0.46 or 0.25% from the previous NSE closing price of ₹181.66 on November 19. The stock initially traded around ₹182 before moving higher towards ₹184 during the pre-market portion of the chart. After regular trading began, shares briefly touched approximately ₹184 before declining towards ₹180. The stock subsequently recovered above ₹182 but failed to sustain the gains. The supplied chart extends to approximately 10:20 AM IST, with shares trading near ₹181.20. The price and percentage change are approximate because an exact last-traded timestamp is not displayed. Wanbury had gained 4.17% in the previous session. Friday’s modest decline followed that recovery, but there is no confirmed evidence that the South Korean inspection announcement caused the stock’s movement.

About Wanbury Limited

Wanbury Limited is an Indian pharmaceutical company headquartered in Navi Mumbai, Maharashtra. The company manufactures active pharmaceutical ingredients and branded formulations for domestic and international markets. Its manufacturing facilities include API plants at Tanuku in Andhra Pradesh and Patalganga in Maharashtra. Wanbury supplies pharmaceutical ingredients to customers across regulated and emerging markets, with a focus on manufacturing quality and regulatory compliance.

Conclusion

Wanbury’s Tanuku API facility has successfully completed South Korea’s MFDS cGMP inspection with zero observations, adding another positive regulatory inspection outcome to the company’s manufacturing operations. The development follows the successful MFDS inspection of its Patalganga facility earlier in 2026. Wanbury shares traded marginally lower on November 20, following the previous session’s gains, while the latest inspection result provides a favourable update on the facility’s compliance with South Korean manufacturing standards.

Source: 

  • https://www.nseindia.in/get-quote/equity/WANBURY/Wanbury-Limited
Disclaimer

The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.

Summarize with AI
Google GeminiChatGPTPerplexity AIAnthropic AIGrok AI
Desktop BannerMobile Banner

Invest Anytime, Anywhere

Get it on Google PlayGet it on App Store

Open Free Demat Account Online

By signing up I certify terms, conditions & privacy policy